Cargando...
New areas of the pharmacotherapy of rheumatic diseases are inhibition of interleukin-6 and interleukin-17
Significant progress related particular to the use of interleukin (IL)-6 and IL17 inhibitors has been made in the pharmacotherapy of rheumatic diseases. IL-6 is a cytokine that has a wide range of biological activity and affects different types of cells. There is evidence for the important role of I...
Gardado en:
| Autor Principal: | |
|---|---|
| Formato: | Artigo |
| Idioma: | Russo |
| Publicado: |
IMA-PRESS LLC
2013-10-01
|
| Series: | Современная ревматология |
| Assuntos: | |
| Acceso en liña: | https://mrj.ima-press.net/mrj/article/view/489 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|